Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1994 Aug;62(8):3391–3395. doi: 10.1128/iai.62.8.3391-3395.1994

Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.

E L Anderson 1, T Bowers 1, C M Mink 1, D J Kennedy 1, R B Belshe 1, H Harakeh 1, L Pais 1, P Holder 1, G M Carlone 1
PMCID: PMC302970  PMID: 8039909

Abstract

A meningococcal vaccine containing group A and C polysaccharides conjugated to CRM197 was evaluated in 50 adults. Vaccinees were entered into one of five groups: 30 adults received a single dose of either 22, 11, or 5.5 micrograms of the conjugated A-C vaccine; 10 received an approved meningococcal vaccine; and 10 received saline injections. Local and systemic reactions to vaccines were recorded, and immune responses were determined. The experimental meningococcal vaccine was well tolerated, with the most frequent reaction being pain at the injection site. Both A and C polysaccharide components of the experimental vaccine were highly immunogenic, and total antibody concentrations 1 month postvaccination were not significantly different from the mean antibody concentrations among adults given the approved meningococcal vaccine. In addition, significant rises in immunoglobulin G, A, and M antibodies to both A and C polysaccharides occurred. Antibody concentrations measured at 6 and 12 months postvaccination had declined but remained significantly higher than prevaccination concentrations. Postvaccination meningococcal group C functional antibody activity increased more than 600-fold for both the polysaccharide and the conjugate vaccines. Further studies of this conjugated meningococcal vaccine are indicated for young children and infants.

Full text

PDF
3391

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams W. G., Deaver K. A., Cochi S. L., Plikaytis B. D., Zell E. R., Broome C. V., Wenger J. D. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA. 1993 Jan 13;269(2):221–226. [PubMed] [Google Scholar]
  2. Artenstein M. S., Gold R., Zimmerly J. G., Wyle F. A., Schneider H., Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970 Feb 19;282(8):417–420. doi: 10.1056/NEJM197002192820803. [DOI] [PubMed] [Google Scholar]
  3. Broadhurst L. E., Erickson R. L., Kelley P. W. Decreases in invasive Haemophilus influenzae diseases in US Army children, 1984 through 1991. JAMA. 1993 Jan 13;269(2):227–231. [PubMed] [Google Scholar]
  4. Carlone G. M., Frasch C. E., Siber G. R., Quataert S., Gheesling L. L., Turner S. H., Plikaytis B. D., Helsel L. O., DeWitt W. E., Bibb W. F. Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay. J Clin Microbiol. 1992 Jan;30(1):154–159. doi: 10.1128/jcm.30.1.154-159.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ceesay S. J., Allen S. J., Menon A., Todd J. E., Cham K., Carlone G. M., Turner S. H., Gheesling L. L., DeWitt W., Plikaytis B. D. Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization. J Infect Dis. 1993 May;167(5):1212–1216. doi: 10.1093/infdis/167.5.1212. [DOI] [PubMed] [Google Scholar]
  6. Costantino P., Viti S., Podda A., Velmonte M. A., Nencioni L., Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine. 1992;10(10):691–698. doi: 10.1016/0264-410x(92)90091-w. [DOI] [PubMed] [Google Scholar]
  7. Dintzis R. Z. Rational design of conjugate vaccines. Pediatr Res. 1992 Oct;32(4):376–385. doi: 10.1203/00006450-199210000-00002. [DOI] [PubMed] [Google Scholar]
  8. Gold R., Lepow M. L. Present status of polysaccharide vaccines in the prevention of meningococcal disease. Adv Pediatr. 1976;23:71–93. [PubMed] [Google Scholar]
  9. Goldschneider I., Gotschlich E. C., Artenstein M. S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969 Jun 1;129(6):1307–1326. doi: 10.1084/jem.129.6.1307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Goldschneider I., Gotschlich E. C., Artenstein M. S. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969 Jun 1;129(6):1327–1348. doi: 10.1084/jem.129.6.1327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gotschlich E. C., Goldschneider I., Artenstein M. S. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med. 1969 Jun 1;129(6):1385–1395. doi: 10.1084/jem.129.6.1385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Granoff D. M., Anderson E. L., Osterholm M. T., Holmes S. J., McHugh J. E., Belshe R. B., Medley F., Murphy T. V. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr. 1992 Aug;121(2):187–194. doi: 10.1016/s0022-3476(05)81186-2. [DOI] [PubMed] [Google Scholar]
  13. Käyhty H., Karanko V., Peltola H., Sarna S., Mäkelä P. H. Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children. J Infect Dis. 1980 Dec;142(6):861–868. doi: 10.1093/infdis/142.6.861. [DOI] [PubMed] [Google Scholar]
  14. Lepow M. L., Goldschneider I., Gold R., Randolph M., Gotschlich E. C. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics. 1977 Nov;60(5):673–680. [PubMed] [Google Scholar]
  15. Mäkelä P. H., Käyhty H., Weckström P., Sivonen A., Renkonen O. V. Effect of group-A meningococcal vaccine in army recruits in Finland. Lancet. 1975 Nov 8;2(7941):883–886. doi: 10.1016/s0140-6736(75)92125-x. [DOI] [PubMed] [Google Scholar]
  16. Peltola H., Mäkelä H., Käyhty H., Jousimies H., Herva E., Hällström K., Sivonen A., Renkonen O. V., Pettay O., Karanko V. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med. 1977 Sep 29;297(13):686–691. doi: 10.1056/NEJM197709292971302. [DOI] [PubMed] [Google Scholar]
  17. Pinner R. W., Onyango F., Perkins B. A., Mirza N. B., Ngacha D. M., Reeves M., DeWitt W., Njeru E., Agata N. N., Broome C. V. Epidemic meningococcal disease in Nairobi, Kenya, 1989. The Kenya/Centers for Disease Control (CDC) Meningitis Study Group. J Infect Dis. 1992 Aug;166(2):359–364. doi: 10.1093/infdis/166.2.359. [DOI] [PubMed] [Google Scholar]
  18. Reingold A. L., Broome C. V., Hightower A. W., Ajello G. W., Bolan G. A., Adamsbaum C., Jones E. E., Phillips C., Tiendrebeogo H., Yada A. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 1985 Jul 20;2(8447):114–118. doi: 10.1016/s0140-6736(85)90224-7. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES